Literature DB >> 16048825

Profiles of club drug users in treatment.

Jane Carlisle Maxwell1, Richard T Spence.   

Abstract

There is little in the literature about treatment of persons with problems with "club" or "party" drugs. This paper looks at the characteristics of individuals admitted to treatment for primary, secondary, or tertiary problems with club drugs such as ecstasy, gamma-hydroxybutyrate (GHB), ketamine, flunitrazepam (Rohypnol), methamphetamine, and hallucinogens (e.g., LSD) in programs funded by the Texas Commission on Alcohol and Drug Abuse. Some 38,350 unduplicated records from 1988 through 2003 of persons admitted with problems with club drugs were compared against users of alcohol or other drugs. Club drug users were more impaired on five of six Addiction Severity Index (ASI) indices at admission and they were more likely to use multiple substances more often. They were more likely than users of alcohol or other drugs to complete treatment, but this varied by drug. At follow-up 90 days after discharge, club drug users continued to report more ASI problems. Profiles of these clients show that ecstasy use has spread beyond the club culture, as indicated by the changes in client demographics over time. GHB clients presented a mixed picture of severe problems at admission and good response to treatment. Hallucinogen clients were young and less likely to complete treatment, while Rohypnol users were on the Texas-Mexico border. The methamphetamine epidemic has resulted in increased admissions, and the proportion of "Ice" smokers has increased. However, methamphetamine clients were less likely to complete treatment and their higher level of problems at admission and follow-up are of concern. Of special note are the indications of co-occurring problems and the need for both mental health and substance dependence treatment for some clients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048825     DOI: 10.1081/JA-200066968

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  8 in total

1.  Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval.

Authors:  Michael Weinborn; Steven Paul Woods; Claire Nulsen; Katherine Park
Journal:  J Clin Exp Neuropsychol       Date:  2011-11-03       Impact factor: 2.475

2.  First injection of ketamine among young injection drug users (IDUs) in three U.S. cities.

Authors:  Stephen E Lankenau; Bill Sanders; Jennifer Jackson Bloom; Dodi Hathazi; Erica Alarcon; Stephanie Tortu; Michael C Clatts
Journal:  Drug Alcohol Depend       Date:  2006-09-18       Impact factor: 4.492

3.  Behavioral effects of gamma-hydroxybutyrate in humans.

Authors:  Alison Oliveto; William Brooks Gentry; Rhonda Pruzinsky; Kishorchandra Gonsai; Thomas R Kosten; Bridget Martell; James Poling
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

4.  Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval.

Authors:  Keith A Trujillo; Colleen Y Heller
Journal:  Behav Brain Res       Date:  2019-10-05       Impact factor: 3.332

5.  Severity of club drug dependence and perceived need for treatment among a sample of adult club drug users in Shanghai, China.

Authors:  Yingying Ding; Na He; Steven Shoptaw; Meiyang Gao; Roger Detels
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-29       Impact factor: 4.328

Review 6.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

7.  Improvement in the pre-hospital care of recreational drug users through the development of club specific ambulance referral guidelines.

Authors:  David M Wood; Shaun L Greene; Graham Alldus; Denise Huggett; Michelle Nicolaou; Kerry Chapman; Fionna Moore; Kim Heather; Nicola Drake; Paul I Dargan
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-06-06

8.  Designer drugs 2015: assessment and management.

Authors:  Michael F Weaver; John A Hopper; Erik W Gunderson
Journal:  Addict Sci Clin Pract       Date:  2015-03-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.